Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Depression is relatively common among patients with epilepsy, but often with predominant atypical symptoms. Some antiepileptic drugs show positive psychotropic effects, but these are not always sufficient to stabilize mood in epilepsy patients. Antidepressants are recommended to treat atypical depression but are not always effective and present a certain risk of seizure provocation. Thus, new treatment options are welcome. Here, we describe three cases of refractory epilepsy with atypical depression in which olanzapine, contrary to its earlier reported proconvulsant effect, showed excellent antidepressant action and resulted in seizure control. Possible mechanisms of this action are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/epd.2018.0977 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spastic cerebral palsy and quality of life in children aged 6-12 years: exploring key associated factors.
Turk J Pediatr
September 2025
Department of Pediatric Neurology, Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Türkiye.
Background: Children with cerebral palsy (CP) may experience epilepsy and challenges with movement, posture, cognition, and musculoskeletal development, which can impact their quality of life (QOL). In this study, we investigated the relationship between demographic and clinical variables as well as QOL in children with spastic CP.
Methods: Children aged 6 to 12 years with CP who were followed-up at our tertiary center were included in this cross-sectional study, regardless of the cause.
Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.
Neurology
October 2025
Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.
Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).
View Article and Find Full Text PDFHigh-resolution electrophysiological mapping of effective connectivity of lateral prefrontal cortex.
Brain
September 2025
Aix Marseille Univ, INSERM, INS, Inst Neurosci Syst, 13005 Marseille, France.
The lateral prefrontal cortex (LPFC) serves as a critical hub for higher-order cognitive and executive functions in the human brain, coordinating brain networks whose disruption has been implicated in many neurological and psychiatric disorders. While transcranial brain stimulation treatments often target the LPFC, our current understanding of connectivity profiles guiding these interventions based on electrophysiology remains limited. Here, we present a high-resolution probabilistic map of bidirectional effective connectivity between the LPFC and widespread cortical and subcortical regions.
View Article and Find Full Text PDFRecessive TMEM167A variants cause neonatal diabetes, microcephaly and epilepsy syndrome.
J Clin Invest
September 2025
Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.
Understanding the genetic causes of diseases affecting pancreatic β cells and neurons can give insights into pathways essential for both cell types. Microcephaly, epilepsy and diabetes syndrome (MEDS) is a congenital disorder with two known aetiological genes, IER3IP1 and YIPF5. Both genes encode proteins involved in endoplasmic reticulum (ER) to Golgi trafficking.
View Article and Find Full Text PDFDevelopment and characterization of an autoresuscitation test for preclinical SUDEP models.
Epilepsia
September 2025
Department of Pharmacology and Neuroscience, Creighton University School of Medicine, Omaha, Nebraska, USA.
The rate of sudden unexpected death in epilepsy (SUDEP) is ~1 per 1000 patients each year. Terminal events reportedly involve repeated and prolonged apnea, suggesting a failure to autoresuscitate. To better understand the mechanisms and identify novel therapeutics, standardized tests to screen for autoresuscitation efficacy are needed in preclinical SUDEP.
View Article and Find Full Text PDF